News

The latest information about changes in pharmacy practice in Alberta.
Reset
Portrait of Patrick Thomson

Pat Thomson installed as president of ACP Council

June 24, 2025

One-year term to begin on July 1, 2025.

Read more ➞

Board room meeting

Council update

June 24, 2025

Highlights from the June 17-18, 2025, Council meeting.

Read more ➞

2024-25 ACP Annual Report cover and feature story pages

2024-25 ACP Annual Report now available online

June 24, 2025

Read highlights of ACP’s year and success stories featuring your pharmacy peers.

Read more ➞

Pharmacy students and provisional pharmacists require direct supervision to administer injections

June 24, 2025

Direct supervision by a supervising pharmacist who has the appropriate authorization and training is always required.

Read more ➞

Two pharmacy professionals working together in the pharmacy

Pharmacists: Preceptor training is now available in Academy!

June 24, 2025

Precepting is a valuable opportunity to foster your personal growth and meaningfully contribute to your profession.

Read more ➞

TPP Alberta logo

Understanding physician prescribing conditions: What you need to know

June 24, 2025

Prescribing conditions placed on prescribers can affect how pharmacists assess prescriptions and support patients.

Read more ➞

Picture of two pharmacy professionals having a discussion with CQI+ logo

Communication is key to successful continuous quality improvement

June 24, 2025

Communication is the fifth key activity of CQI+.

Read more ➞

Do you have a new pharmacist graduate on your team?

June 10, 2025

Licensees: Ensure new pharmacist grads are listed on the clinical pharmacist register before practising independently.

Read more ➞

Picture of two pharmacy professionals having a discussion with CQI+ logo

Improving policies and procedures helps reduce practice incidents

June 10, 2025

Improve is the fourth key activity of CQI+.

Read more ➞

Unauthorized compounding of semaglutide-containing products is not permitted

June 10, 2025

Health Canada’s position on the unauthorized manufacturing of products sold as compounded glucagon like peptide 1 (GLP-1) receptor agonists.

Read more ➞